Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 10, 2026 UCBN News, Syndication Comments Off on Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the results of a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis (AD) conducted by the Company’s partner in China, Simcere Pharmaceutical Co., Ltd. (Simcere), will be presented in the Late-Breaking Research session at the 2026 AAD Annual Meeting, which takes place March 27-31, 2026, in Denver, Colorado.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

News

Charlotte’s Web™ Expands its Brightside Line with Launch of Knockout Hemp THC Sleep Gummies

October 14, 2025 UCBN News, Syndication Comments Off on Charlotte’s Web™ Expands its Brightside Line with Launch of Knockout Hemp THC Sleep Gummies

The fourth addition to its hemp-derived THC product lineup, Knockout expands Charlotte’s Web’s Brightside collection into the sleep market by combining cannabinoids, clean ingredients, and fast-acting delivery technology to support quality sleep. LOUISVILLE, Colo., Oct. […]